Co-Expression of Lewis y Antigen with Human Epididymis Protein 4 in Ovarian Epithelial Carcinoma

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhuang, Huiyu ^a   Gao, Jian ^a   Hu, Zhenhua ^a   Liu, Juanjuan ^a   Liu, Dawo ^a   Lin, Bei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; ISOPROTEIN; LEWIS Y ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; BLOOD GROUP LEWIS SYSTEM; CANCER CLASSIFICATION; CARCINOMA CELL; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE ASSOCIATION; DOUBLE LABELING IMMUNOFLUORESCENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROTEINS; YOUNG ADULT;

EID: 84880694749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068994     Document Type: Article

References (22)

1. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, et al. (1999) Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238(2): 375-385.
2. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, et al. (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63(13): 3695-3700.
3. Drapkin R, von Horsten HH, Lin Y, Mok Samuel C, Crum CP, et al. (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6): 2162-2169.
4. Moore RG, McMeekin DS, Brown AK, DiSilvestro Paul, Miller M Craig, et al. (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1): 40-46.
5. Moore RG, Brown AK, Miller MC, Skates Steven, Allard WJ, et al. (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2): 402-408.
6. Moriwaki K, Miyoshi E, (2010) Fucosylation and gastrointestinal cancer. World J Hepatol 2(4): 151-161.
7. Chhieng DC, Rodriguez-Burford C, Talley LI, Sviglin H, Stockard CR, et al. (2003) Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 34(10): 1016-1021.
8. Li Q, Liu S, Lin B, Yan L, Wang Y, et al. (2010) Expression and Correlation of Lewis y Antigen and Integrins α5 and β1 in Ovarian Serous and Mucinous Carcinoma. Int. J. Gynecol. Cancer 20(9): 1482-1489.
9. Yin BW, Finstad CL, Kitamura K, Federici MG, Welshinger M, et al. (1996) Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int. J. Cancer 65(4): 406-412.
10. Liu JJ, Lin B, Hao YY, Li FF, Liu DW, et al. (2010) Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol. Rep 23(3): 833-841.
11. Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, et al. (2010) Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1, 2-fucosyltransferase gene. Biochimie 92(7): 852-857.
12. Gao L, Yan L, Lin B, Gao J, Liang X, et al. (2011) Enhancive Effects of Lewis y Antigen on CD44-mediated Adhesion and Spreading of Human Ovarian Cancer Cell Line RMG-I. Journal of Experimental & Clinical Cancer Research 30(1): 15.
13. Bingle L, Singleton V, Bingle CD, (2002) The putative ovarian tumor maker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21(17): 2768-2773.
14. Tokuishi K, Yamashita SI, Ohbo K, Kawahara K, (2012) Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumor Biol 33: 103-109.
15. Lu R, Sun X, Xiao R, Zhou L, Gao X, et al. (2012) Human epididymis protein 4(HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem. Biophys. Res. Commun 419(2): 274-280.
16. Klinger M, Farhan H, Just H, Drobny H, Himmler G, et al. (2004) Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 64(3): 1087-1093.
17. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, et al. (2006) Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J. Biol. Chem 281(5): 2572-2577.
18. Orczyk-Pawiłowicz M, (2007) The role of fucosylation of glycoconjugates in health and disease. Postepy Hig Med Dosw (online). 61: 240-252.
19. Roseman S, (2001) Reflections on glycobiology. J. Biol. Chem 276(45): 41527-41542.
20. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, et al. (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22(3): 802-807.
21. Mita Y, Aoyagi Y, Suda T. Asakura H, (2000) Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J. Hepatol 32(6): 946-954.
22. Food and Drug Administration, HHS (2005) Medical devices: immunology and microbiology devices; classification of AFP-L3% immunological test systems. Final rule. Fed Regist 70(191): 57748-57750.